22nd Century Group Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 16% sequential revenue growth and improved gross loss, driven by expanding VLN retail distribution and early consumer adoption. The company targets 5,000 outlets by year-end and expects stronger momentum in the second half as marketing investments ramp up.
Fiscal Year 2025
-
2025 was a pivotal year, shifting from restructuring to growth, launching VLN low-nicotine products and expanding retail presence. Financials improved with reduced losses and a debt-free balance sheet, while new capital supports 2026 growth plans.
-
Transitioning to a growth phase, the company is now debt-free and focused on profitable branded products, with a cash runway into 2026. VLN products target smokers seeking to quit, with U.S. expansion prioritized and South Korea on hold.
-
Q3 2025 saw a strategic shift to higher-margin branded VLN products, improved balance sheet with no debt, and $14M in cash post-quarter. The company targets EBITDA break-even by Q2 2026, with expanding VLN distribution and strong alignment with FDA harm reduction goals.
-
The company is shifting focus to branded, FDA-compliant low-nicotine products, with VLN cigarettes leading the market and expanding into 2,000 retail outlets. Scientific studies validate VLN's effectiveness, and national rollout is underway, targeting profitability by 2026.
-
Q2 2025 saw a revenue decline to $4M and continued net losses as the business shifts from low-margin CMO to high-margin branded VLN products. Profitability is now targeted for H1 2026, with new product launches and expanded distribution expected to drive gross margin improvement.
-
A pioneering nicotine harm reduction company is expanding its FDA-authorized low nicotine product line, leveraging new branding, partner collaborations, and a broadened distribution network. Financial recovery is underway, with a focus on innovation, state approvals, and reaching break-even by Q4 2025.
-
Q1 2025 saw 50% sequential revenue growth and improved margins, with strong momentum in value and reduced-nicotine brands. The company is on track for break-even EBITDA in the second half of 2025, supported by expanded distribution and a strengthened balance sheet.
-
The company is relaunching its FDA-authorized low-nicotine cigarette brands with new marketing, expanding distribution through key retail partnerships, and targeting all 50 states by July 2025. Financial turnaround efforts have led to profitability at the SKU level, with EBITDA break-even now targeted for Q4 2025.
Fiscal Year 2024
-
Major restructuring in 2024 led to reduced debt, lower costs, and a focus on tobacco, with VLN and CMO businesses positioned for growth in 2025. Revenue and margins dipped during contract transitions, but profitability and break-even EBITDA are targeted for Q4 2025.
-
Q3 revenue declined sequentially due to lower shipment volumes, but cost cuts and restructuring led to improved profitability metrics and a stronger balance sheet. The company is focused on expanding CMO and VLN product lines, targeting break-even by Q1 2025.
-
A unique low-nicotine cigarette is being positioned as a new retail category, with strong FDA backing and no direct competitors. The company is expanding distribution, improving margins, and expects positive cash flow next quarter as it leverages R&D and contract manufacturing partnerships.
-
Net loss narrowed dramatically year-over-year, with revenue stabilizing and operating expenses sharply reduced. Contract manufacturing is ramping up, and a major rebranding of the VLN product is underway, targeting profitability and cash-positive operations by Q1 2025.